| Titre : |
Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving |
| Type de document : |
document électronique |
| Auteurs : |
Saul Shiffman, Auteur ; C.A. Elash, Auteur ; Stephanie M. Paton, Auteur ; Chad J. Gwaltney, Auteur ; Jean A. Paty, Auteur ; D.B. Clarke, Auteur ; K.S. Liu, Auteur ; Michael E. Di Marino, Auteur |
| Editeur : |
Society for the study of addiction to alcohol and other drugs |
| Année de publication : |
2000 |
| Collection : |
Addiction num. 95(8) |
| Importance : |
p.1185-1195 |
| Langues : |
Anglais (eng) |
| Catégories : |
[TABAC] sevrage tabagique:efficacité du sevrage
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:patch à la nicotine
|
| Index. décimale : |
TA 6.2.3.1.2 Transcutané |
| Résumé : |
Aims: To compare a transdermal nicotine patch designed for 24-hour wear with one designed for 16-hour wear for relief of craving and withdrawal, particularly in the morning hours.
Design: Smokers were randomly assigned to use one of two common patch regimens: NicoDerm/NiQuitin (24-hour wear, 21 mg nicotine) or Nicotrol/Nicorette (16-hour wear, 15 mg). In a double-dummy design, participants wore two patches during the day, one active, one placebo and one patch while sleeping.
Setting: A smoking cessation research clinic.
Participants: Two hundred and forty-four smokers who suffered morning cravings.
Intervention: Two patch formulations approved and marketed for over-the-counter use in the US--NicoDerm CQ (labeled as 21 mg over 24 hours) and Nicotrol (labeled as 15 mg over 16 hours)--were each used according to its instructions. Smokers also received behavioral counseling.
Measurements: For a week of baseline and 2 weeks after quitting, smokers used palm-top computers to assess craving and withdrawal symptoms several times each day.
Findings: The 21 mg/24-hour patch yielded consistently better control of craving, not only during the morning hours, but throughout the day, and over the 2-week period of abstinence. Additionally, the 21 mg/24-hour patch yielded greater reductions in anxiety, irritability and restlessness. Smokers using the 21 mg/24-hour dosing regimen also experienced longer abstinence than those using the 15 mg/16-hour patch.
Conclusions: These findings demonstrate that 24-hour dosing with a 21 mg patch affords superior relief of craving and withdrawal during the first 2 weeks of abstinence, when symptoms are at their peak, and when relapse is most likely. They confirm the importance of dosing parameters in nicotine replacement products. |
| En ligne : |
https://doi.org/10.1046/j.1360-0443.2000.95811855.x |
| Format de la ressource électronique : |
Article en ligne |
| Permalink : |
https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10343 |
|
Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving (2000)
